Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
What to expect in Puerto Rico's Democratic presidential primaryExperts warn about Venezuela's broken HPV vaccine promisesTrump downplays deadly Charlottesville rally with comparison to campus protestsMartine McCutcheon admits she's 'feeling c***py' as she shares her health diagnosis with fansAmanda Holden flashes her toned abs in plunging crop top as she wows in daring ensembleACC Spring Wrap: League champ Florida State and ACC deal with quarterback changesParis Hilton flashes her toned midriff and bronzed legs in a racy pink cutU.S. labor secretary says UAW win at Tennessee Volkswagen plant shows southern workers back unionsNative American tribes want US appeals court to weigh in on $10B SunZia energy transmission projectGary Sánchez pinch hits for 2
0.126s , 6503.3984375 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,Stellar Station news portal